These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36149441)

  • 1. [Relevance of clonal hematopoiesis for cellular therapies].
    Teipel R; von Bonin M; Stölzel F; Schetelig J; Thiede C; Bornhäuser M
    Inn Med (Heidelb); 2022 Nov; 63(11):1126-1132. PubMed ID: 36149441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal hematopoiesis in hematopoietic stem cell transplantation.
    Wilk CM; Manz MG; Boettcher S
    Curr Opin Hematol; 2021 Mar; 28(2):94-100. PubMed ID: 33394723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation.
    Nawas MT; Schetelig J; Damm F; Levine RL; Perales MA; Giralt SA; VanDenBrink MR; Arcila ME; Zehir A; Papaemmanuil E; Klussmeier A; Schmidt AH; Maiwald S; Bolton KL; Tamari R
    Blood Rev; 2021 Mar; 46():100744. PubMed ID: 32896435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse.
    Newell LF; Williams T; Liu J; Yu Y; Chen Y; Booth GC; Knight RJ; Goslee KR; Cook RJ; Leonard J; Meyers G; Traer E; Press RD; Fan G; Wang Y; Raess PW; Maziarz RT; Dunlap J
    Transplant Cell Ther; 2021 Aug; 27(8):662.e1-662.e9. PubMed ID: 33901720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Cao XY; Li JJ; Lu PH; Liu KY
    Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
    Lv Z; Luo F; Chu Y
    Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.
    Oran B; Champlin RE; Wang F; Tanaka T; Saliba RM; Al-Atrash G; Garcia-Manero G; Kantarjian H; Cao K; Shpall EJ; Alousi AM; Mehta RS; Popat U; Futreal A; Takahashi K
    Leukemia; 2022 Jan; 36(1):257-262. PubMed ID: 34135465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph
    Han L; Zhao R; Yang J; Zu Y; Liu Y; Zhou J; Li L; Huang Z; Zhang J; Gao Q; Song Y; Zhou K
    Front Immunol; 2022; 13():965932. PubMed ID: 36225940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation.
    Boettcher S; Wilk CM; Singer J; Beier F; Burcklen E; Beisel C; Ventura Ferreira MS; Gourri E; Gassner C; Frey BM; Schanz U; Skoda RC; Ebert BL; Brummendorf TH; Beerenwinkel N; Manz MG
    Blood; 2020 Apr; 135(18):1548-1559. PubMed ID: 32181816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy.
    Kapadia CD; Rosas G; Thakkar SG; Wu M; Torrano V; Wang T; Grilley BJ; Heslop HE; Ramos CA; Goodell MA; Lulla PD
    Cytotherapy; 2024 Mar; 26(3):261-265. PubMed ID: 38149948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2020; 11():1804. PubMed ID: 32973756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.
    Frick M; Chan W; Arends CM; Hablesreiter R; Halik A; Heuser M; Michonneau D; Blau O; Hoyer K; Christen F; Galan-Sousa J; Noerenberg D; Wais V; Stadler M; Yoshida K; Schetelig J; Schuler E; Thol F; Clappier E; Christopeit M; Ayuk F; Bornhäuser M; Blau IW; Ogawa S; Zemojtel T; Gerbitz A; Wagner EM; Spriewald BM; Schrezenmeier H; Kuchenbauer F; Kobbe G; Wiesneth M; Koldehoff M; Socié G; Kroeger N; Bullinger L; Thiede C; Damm F
    J Clin Oncol; 2019 Feb; 37(5):375-385. PubMed ID: 30403573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The crossroads of cancer therapies and clonal hematopoiesis.
    Singh A; Balasubramanian S
    Semin Hematol; 2024 Feb; 61(1):16-21. PubMed ID: 38403501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.